Cyanobacterial Cyclopeptides as Lead Compounds to Novel Targeted Cancer Drugs

Abstract

Cyanobacterial cyclopeptides, including microcystins and nodularins, are considered a health hazard to humans due to the possible toxic effects of high consumption. From a pharmacological standpoint, microcystins are stable hydrophilic cyclic heptapeptides with a potential to cause cellular damage following uptake via organic anion-transporting polypeptides (OATP). Their intracellular biological effects involve inhibition of catalytic subunits of protein phosphatase 1 (PP1) and PP2, glutathione depletion and generation of reactive oxygen species (ROS). Interestingly, certain OATPs are prominently expressed in cancers as compared to normal tissues, qualifying MC as potential candidates for cancer drug development. In the era of targeted cancer therapy, cyanotoxins comprise a rich source of natural cytotoxic compounds with a potential to target cancers expressing specific uptake transporters. Moreover, their structure offers opportunities for combinatorial engineering to enhance the therapeutic index and resolve organ-specific toxicity issues. In this article, we revisit cyanobacterial cyclopeptides as potential novel targets for anticancer drugs by summarizing existing biomedical evidence, presenting structure-activity data and discussing developmental perspectives.

DOI: 10.3390/md8030629

Extracted Key Phrases

7 Figures and Tables

Statistics

050010002011201220132014201520162017
Citations per Year

1,162 Citations

Semantic Scholar estimates that this publication has 1,162 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@inproceedings{Sainis2010CyanobacterialCA, title={Cyanobacterial Cyclopeptides as Lead Compounds to Novel Targeted Cancer Drugs}, author={Ioannis Sainis and Demosthenes Fokas and Katerina Vareli and Andreas G. Tzakos and Valentinos Kounnis and Evangelos Briasoulis}, booktitle={Marine drugs}, year={2010} }